Working with TipRanks
Follow Us
Stocks
ETFs
Options
Crypto
Research Tools
Calendars
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bioxcel Therapeutics Inc (BTAI)
NASDAQ:BTAI
Bioxcel Therapeutics (BTAI) Stock Price & Analysis
1,141 Followers
BTAI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.23 - $34.13
Previous Close$3.8
Volume693.45K
Average Volume (3M)3.27M
Market Cap
$111.24M
Enterprise Value$120.90M
Total Cash (Recent Filing)$89.96M
Total Debt (Recent Filing)$99.62M
Price to Earnings (P/E)-0.5
Beta1.55
Next Earnings
Mar 07, 2024EPS Estimate
-$0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.36
Shares Outstanding29,272,671
10 Day Avg. Volume1,070,327
30 Day Avg. Volume3,274,172
Standard Deviation0.35
R-Squared0.02
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)-2.81
Price to Sales (P/S)467.38
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue97.34
Enterprise Value/Gross Profit340.56
Enterprise Value/Ebitda-0.61
Forecast
1Y Price Target
$10.50Price Target Upside169.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Bioxcel Therapeutics News
Ownership Overview
0.00% Insiders
16.30% Mutual Funds
9.15% Other Institutional Investors
74.55% Public Companies and Individual Investors
BTAI FAQ
What was Bioxcel Therapeutics Inc’s price range in the past 12 months?
Bioxcel Therapeutics Inc lowest stock price was $2.23 and its highest was $34.13 in the past 12 months.
What is Bioxcel Therapeutics Inc’s market cap?
Currently, no data Available
When is Bioxcel Therapeutics Inc’s upcoming earnings report date?
Bioxcel Therapeutics Inc’s upcoming earnings report date is Mar 07, 2024 which is in 96 days.
How were Bioxcel Therapeutics Inc’s earnings last quarter?
Bioxcel Therapeutics Inc released its earnings results on Nov 14, 2023. The company reported -$1.72 earnings per share for the quarter, missing the consensus estimate of -$1.274 by -$0.446.
Is Bioxcel Therapeutics Inc overvalued?
According to Wall Street analysts Bioxcel Therapeutics Inc’s price is currently Undervalued.
Does Bioxcel Therapeutics Inc pay dividends?
Bioxcel Therapeutics Inc does not currently pay dividends.
What is Bioxcel Therapeutics Inc’s EPS estimate?
Bioxcel Therapeutics Inc’s EPS estimate is -$0.91.
How many shares outstanding does Bioxcel Therapeutics Inc have?
Bioxcel Therapeutics Inc has 29,272,670 shares outstanding.
What happened to Bioxcel Therapeutics Inc’s price movement after its last earnings report?
Bioxcel Therapeutics Inc reported an EPS of -$1.72 in its last earnings report, missing expectations of -$1.274. Following the earnings report the stock price went down -23.412%.
Which hedge fund is a major shareholder of Bioxcel Therapeutics Inc?
Among the largest hedge funds holding Bioxcel Therapeutics Inc’s share is Driehaus Capital Management LLC. It holds Bioxcel Therapeutics Inc’s shares valued at 56K.
---
Bioxcel Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.50 (169.92% Upside)
$10.50 (169.92% Upside)
Blogger Sentiment
Bullish
BTAI Sentiment 60%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 6.0%
Last 30 Days ▲ 6.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.06%
12-Months-Change
Fundamentals
Return on Equity
-489.95%
Trailing 12-Months
Asset Growth
-58.97%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Bioxcel Therapeutics Inc
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.
---
Top 5 ETFs holding BTAI
Vanguard Total Stock Market ETF
$2.57M
Schwab U.S. Broad Market ETF
$80.72K
iShares Russell 3000 ETF
$14.47K
Vanguard Russell 3000 ETF
$5.06K
UBS (Irl) ETF PLC - MSCI USA Select Factor Mix UCITS ETF Accum A Hedged CHF
$433.92
Up to five ETFs with an Outperform Smart Score that hold BTAI. The ETFs are listed according to market value of BTAI within the ETF
Arcutis Biotherapeutics
―
Ultragenyx Pharmaceutical
―
Orchard Therapeutics
―
Corbus Pharmaceuticals
―
---